Skip to main content Skip to footer
Novakand Pharma
  • Home
  • About us
    • Our Business
    • Strategy and business model
    • Management
    • Board of Directors
    • Contact us
  • Pipeline
    • Our Science
    • Pipeline overview
    • Projects
      • Rugocrixan
      • Fosrugocrixan
    • Business Development
    • IP
    • Publications
  • Therapeutic areas
    • Myocardial infarction
    • Ovarian cancer
  • Investors
    • Presentations
    • Press Releases
    • Financial Reports
    • Financial Calendar
    • Events
    • The Share
    • Sustainability
    • Corporate Governance
      • Articles of Association
      • Annual General Meeting
      • Board Committee
      • Board
      • CEO and Management
      • Auditors
      • Certified Adviser
  • Home
  • About us
    • Our Business
    • Strategy and business model
    • Management
    • Board of Directors
    • Contact us
  • Pipeline
    • Our Science
    • Pipeline overview
    • Projects
      • Rugocrixan
      • Fosrugocrixan
    • Business Development
    • IP
    • Publications
  • Therapeutic areas
    • Myocardial infarction
    • Ovarian cancer
  • Investors
    • Presentations
    • Press Releases
    • Financial Reports
    • Financial Calendar
    • Events
    • The Share
    • Sustainability
    • Corporate Governance
      • Articles of Association
      • Annual General Meeting
      • Board Committee
      • Board
      • CEO and Management
      • Auditors
      • Certified Adviser
  • Svenska
Start>News>English

English

  • Kancera provides operational update

    20 November 2015

  • Interim Report for Kancera AB (publ) Q3 2015. January 1 – September 30, 2015.

    20 November 2015

  • Kancera provides operational update on the ROR and Fractalkine projects

    1 October 2015

  • Kancera evaluates immuno-oncology drug candidate

    8 September 2015

  • Interim Report for Kancera AB (publ) Q2 2015, January 1 – June 30, 2015

    21 August 2015

  • Interim Report for Kancera AB (publ) Q1 2015 January 1 – March 31, 2015

    22 May 2015

  • Kancera provides operational update on the cancer projects

    5 May 2015

  • Full Year Report for Kancera AB (publ) Q4 2014 January 1 – December 31, 2014

    20 February 2015

  • Kancera provides operational update on the ROR project

    3 February 2015

  • Kancera provides operational update on the HDAC6 project

    10 December 2014

+46 (0)8 5012 60 80Nanna Svarts väg 4, 171 65 Solna, Sweden

Content

  • Home
  • About us
  • Pipeline
  • Therapeutic areas
  • Investors

Shortcuts

  • Press Releases
  • Financial Reports
  • Financial Calendar
  • Website Policy

Copyright © 2025 Novakand AB. All Rights Reserved. Design by Clavis Communications